Dysbiosis gut microbiota associated with inflammation and impaired mucosal immune function in intestine of humans with non-alcoholic fatty liver disease

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Jiang, Weiwei ^a   Wu, Na ^a   Wang, Xuemei ^a   Chi, Yujing ^a   Zhang, Yuanyuan ^a   Qiu, Xinyun ^a   Hu, Ying ^a   Li, Jing ^a   Liu, Yulan ^a  

^a PEKING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 6; RNA 16S; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; BACTERIUM; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CROSS-SECTIONAL STUDY; CYTOLOGY; DYSBIOSIS; FEMALE; GENETICS; HUMAN; IMMUNOLOGY; INFLAMMATION; INTESTINE MUCOSA; MALE; METABOLISM; MICROBIOLOGY; MICROFLORA; MIDDLE AGED; NONALCOHOLIC FATTY LIVER; PATHOLOGY; SEQUENCE ANALYSIS; TIGHT JUNCTION;

ADULT; AGED; BACTERIA; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CROSS-SECTIONAL STUDIES; DYSBIOSIS; FEMALE; HUMANS; INFLAMMATION; INTERFERON-GAMMA; INTERLEUKIN-6; INTESTINAL MUCOSA; MALE; MICROBIOTA; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; RNA, RIBOSOMAL, 16S; SEQUENCE ANALYSIS, RNA; TIGHT JUNCTIONS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84937576853     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep08096     Document Type: Article

References (34)

1. Torres, D. M., Williams, C. D.&Harrison, S. A. Features, diagnosis, and treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 10, 837-858 (2012).
2. Tilg, H., Moschen, A. R. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 52, 1836-1846 (2010).
3. Abu-Shanab, A., Quigley, E. M. The role of the gut microbiota in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 7, 691-701 (2010).
4. Moschen, A. R., Kaser, S., Tilg, H. Non-alcoholic steatohepatitis: a microbiotadriven disease. Trends Endocrinol Metab 24, 537-545 (2013).
5. Turnbaugh, P. J. et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444, 1027-1031 (2006).
6. Le Roy, T. et al. Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice. Gut 62, 1787-1794 (2013).
7. Hooper, L. V., Littman, D. R., Macpherson, A. J. Interactions between the microbiota and the immune system. Science 336, 1268-1273 (2012).
8. Su, L. et al. Intestinal immune barrier integrity in rats with nonalcoholic hepatic steatosis and steatohepatitis. Chin Med J (Engl) 125, 306-311 (2012).
9. Raman, M. et al. Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 11, 868-875 e861-863 (2013).
10. Mouzaki, M. et al. Intestinal microbiota in patients with nonalcoholic fatty liver disease. Hepatology 58, 120-127 (2013).
11. Zhu, L. et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology 57, 601-609 (2013).
12. Son, G., Kremer, M., Hines, I. N. Contribution of gut bacteria to liver pathobiology. Gastroenterol Res Pract 2010, 1-13 (2010).
13. Compare, D. et al. Gut-liver axis: the impact of gut microbiota on non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 22, 471-476 (2012).
14. Miele, L. et al. Gut-liver axis and microbiota in NAFLD: insight pathophysiology for novel therapeutic target. Curr Pharm Des 19, 5314-5324 (2013).
15. Fallucca, F., Porrata, C., Fallucca, S., Pianesi, M. Influence of diet on gut microbiota, inflammation and type 2 diabetes mellitus. First experience with macrobiotic Ma-Pi 2 diet. Diabetes Metab Res Rev 30 Suppl 1, 48-54 (2014).
16. Cani, P. D. et al. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 58, 1091-1103 (2009).
17. Cani, P. D., Osto, M., Geurts, L., Everard, A. Involvement of gut microbiota in the development of low-grade inflammation and type 2 diabetes associated with obesity. Gut Microbes 3, 279-288 (2012).
18. Small, C. L., Reid-Yu, S. A., McPhee, J. B., Coombes, B. K. Persistent infection with Crohn's disease-associated adherent-invasive Escherichia coli leads to chronic inflammation and intestinal fibrosis. Nat Commun 4, 1957 (2013).
19. Cuevas-Ramos, G. et al. Escherichia coli inducesDNA damage in vivo and triggers genomic instability in mammalian cells. Proc Natl Acad Sci USA 107, 11537-11542 (2010).
20. Prorok-Hamon, M. et al. Colonic mucosa-associated diffusely adherent afaC1 Escherichia coli expressing lpfA and pks are increased in inflammatory bowel disease and colon cancer. Gut 63, 761-770 (2014).
21. Al-Jashamy, K., Murad, A., Zeehaida, M., Rohaini, M., Hasnan, J. Prevalence of colorectal cancer associated with Streptococcus bovis among inflammatory bowel and chronic gastrointestinal tract disease patients. Asian Pac J Cancer Prev 11, 1765-1768 (2010).
22. Cucchiara, S., Iebba, V., Conte, M. P., Schippa, S. The microbiota in inflammatory bowel disease in different age groups. Dig Dis 27, 252-258 (2009).
23. Scheppach, W.&Weiler, F. The butyrate story: old wine in new bottles CurrOpin Clin Nutr Metab Care 7, 563-567 (2004).
24. Kles, K. A., Chang, E. B. Short-chain fatty acids impact on intestinal adaptation, inflammation, carcinoma, and failure. Gastroenterology 130, S100-105 (2006).
25. Flint, H. J., Bayer, E. A., Rincon, M. T., Lamed, R., White, B. A. Polysaccharide utilization by gut bacteria: potential for new insights from genomic analysis. Nat Rev Microbiol 6, 121-131 (2008).
26. Wu, G.D. et al. Linking long-term dietary patternswith gut microbial enterotypes. Science 334, 105-108 (2011).
27. De Filippo, C. et al. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proc Natl Acad Sci USA 107, 14691-14696 (2010).
28. Kim, C. S. et al. Visceral fat accumulation induced by a high-fat diet causes the atrophy of mesenteric lymph nodes in obese mice. Obesity (Silver Spring) 16, 1261-1269 (2008).
29. Tanaka, S. et al. Impaired immunity in obesity: suppressed but reversible lymphocyte responsiveness. Int J Obes Relat Metab Disord 17, 631-636 (1993).
30. Tanaka, S., Isoda, F., Ishihara, Y., Kimura, M., Yamakawa, T. T lymphopaenia in relation to body mass index and TNF-alpha in human obesity: adequate weight reduction can be corrective. Clin Endocrinol (Oxf) 54, 347-354 (2001).
31. Norimatsu, M. et al. Lipopolysaccharide-induced apoptosis in swine lymphocytes in vivo. Infect Immun 63, 1122-1126 (1995).
32. Nielsen, J. S. et al. Rough-Form-Lipopolysaccharide Increase Apoptosis in Human CD4(1) and CD8(1) T-Lymphocytes. Scand J Immunol 75, 193-202 (2012).
33. Chalasani, N. et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 142, 1592-1609 (2012).
34. Cong, X. et al. Activation of transient receptor potential vanilloid subtype 1 increases expression and permeability of tight junction in normal and hyposecretory submandibular gland. Lab Invest 92, 753-768 (2012).